Evaluation of the effect of Eryngium billardieri in diabetic patients

Evaluation of the effect of Eryngium billardieri capsule on blood sugar in type 2 diabetic patients who received oral agents

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211229053563N1

Enrollment

Registered

2022-05-31

Start date

2022-06-11

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group:Daily 2 capsules including 500 mg Eryngium. Intervention 2: Control group: Daily 2 capsules including 500 mg placebo.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: All of the patients are over 20 years of age with type 2 diabetes, receiving oral medications (Metformin and/or Pioglitazone, etc), Hb.A1C > 7.5

Exclusion criteria

Exclusion criteria: Pregnancy and lactation, Creatinine clearance less than 30 ml/min, Severe liver failure, Patients treated with newer diabetes drugs (Incretin Mimetics and SGLT2 inhibitors), Hb.A1C <7.5

Design outcomes

Primary

Measure	Time frame
Determine Fasting Blood Sugar (FBS). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Glycosylated Hemoglobin (HbA1C). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.	—

Measure

Time frame

Determine Fasting Blood Sugar (FBS). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Glycosylated Hemoglobin (HbA1C). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.

—

Secondary

Measure	Time frame
Determination level of Triglyceride. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Low-density Lipoprotein (LDL). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of High-density Lipoprotein (HDL). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Blood pressure measurement. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Using a barometer.	—

Measure

Time frame

Determination level of Triglyceride. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of Low-density Lipoprotein (LDL). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Determination level of High-density Lipoprotein (HDL). Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Use of Auto-Analyzer machine and Spectrophotometric method.;Blood pressure measurement. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Using a barometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Rostami Alamdari

Tabriz University of Medical Sciences

zahrarostamialamdari@gmail.com098 41 33253171

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026